AstraZeneca's Pipeline Momentum: Cancer Wins and Obesity Deals Fuel Valuation Questions
AstraZeneca secures key regulatory nods for cancer drugs and strikes a new metabolic disease partnership, driving its soaring share price and intensifying the debate over its future growth trajectory.